spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Immune Globulin 

 HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2018
Grifols HyperRAB(R) (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch
 HSMN NewsFeed - 8 Feb 2017
Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2016
Kamada Announces Extension of GLASSIA(R) Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020
Biopharmaceuticals Distribution Licensing
 HSMN NewsFeed - 1 Sep 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2014
Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Apr 2012
Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jul 2011
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2011
FDA Approves Marketing of RMS Subcutaneous Needle Sets
Devices FDA
 HSMN NewsFeed - 1 Dec 2010
Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex(R) for Fast Track Development
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 14 Oct 2010
Talecris Biotherapeutics Receives FDA Approval for Gamunex(R)-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2010
Privigen(R) Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Data Support Hizentra(R) Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2010
Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Jan 2010
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2009
Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jul 2009
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID with rHuPH20 Enzyme
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
Kawasaki Disease Treated with Plasma-Derived Therapy
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2008
FDA Grants Approval to Talecris Biotherapeutics for Gamunex(R) as a Treatment for Neurological Disorder CIDP in the United States
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Aug 2008
Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Biopharmaceuticals Distribution Personnel
 HSMN NewsFeed - 8 May 2008
FDA Grants Priority Review of Gamunex(R) as a Treatment for Neurological Disorder CIDP
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2008
Cangene's anti-hepatitis B product granted orphan-drug exclusive approval by the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2008
Positive Results from Phase III Trial of Gamunex(R) in Patients with CIDP
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 16 Nov 2007
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2007
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2007
Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 28 Aug 2007
Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Aug 2007
Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
Nabi Biopharmaceuticals Appoints Matthew W. Kalnik, Ph.D., as Vice President, Business Development and Project Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 May 2007
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2007
Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim(TM)
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2007
FDA approves Cangene's HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Apr 2007
FDA approves Cangene's HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Feb 2007
Nabi Biopharmaceuticals Announces Resignation of Thomas McLain as CEO and Appointment of Leslie Hudson as Interim CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 2 Jan 2007
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
Biopharmaceuticals Group Purchasing
 HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2006
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Sep 2006
Nabi Biopharmaceuticals Board Authorizes Exploration of Strategic Alternatives to Further Enhance Shareholder Value
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2006
Nabi Biopharmaceuticals Releases New Data which Demonstrate Superior Serum Phosphorus Control with PhosLo(R) (calcium acetate) over Sevelamer
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2006
Nabi Biopharmaceuticals Receives Positive Opinion from FDA Blood Products Advisory Committee for Nabi-HB(TM) Intravenous
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2006
Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir(R) in Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jun 2006
Nabi Biopharmaceuticals Names Jordan I. Siegel Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2006
Inhibitex Provides Update on Status of Veronate(R) Program
Biopharmaceuticals
 HSMN NewsFeed - 3 Apr 2006
Nabi Biopharmaceuticals Acquires Exclusive North American Commercialization Rights to Phase III Antibody Product for Prevention and Treatment of Rejection Following Organ Transplantation
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2006
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Mar 2006
Phase III Clinical Study Shows Vivaglobin(R), a New Subcutaneous Immunoglobulin, Is Safe and Effective In Treating Patients With Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2006
Premier's New Plasma and Recombinant Program Helps Hospitals Acquire Products in Short Supply
Biopharmaceuticals Group Purchasing
 HSMN NewsFeed - 1 Feb 2006
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for Civacir to Prevent Hepatitis C Re-infection in Liver Transplants
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2006
Nabi Biopharmaceuticals' Mark L. Smith Resigns as Company's CFO, Effective on or Around March 1, 2006
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2006
MedAssets Names Blood Diagnostics, Inc. as an Awarded Blood Fraction Distributor
Biopharmaceuticals Group Purchasing
 HSMN NewsFeed - 25 Jan 2006
Nabi Biopharmaceuticals Provides Update on Strategic Direction of NicVAX(TM) Program
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2006
Baxter Receives Marketing Authorization From the European Commission for KIOVIG to Treat Immunodeficiencies
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Jan 2006
ZLB Behring Announces FDA Approval of Vivaglobin(R) - The First Subcutaneous Immunoglobulin Replacement Therapy Approved in the U.S.
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 68

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 68 additional stories matching:
Immune Globulin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.